Hermetica Superfood Encyclopedia
The Short Answer
Bridelia ferruginea leaf and stem bark extracts are rich in phenolic compounds and flavonoids that exert antioxidant, anticholinesterase, tyrosinase-inhibitory, and antimicrobial effects through radical scavenging and enzyme inhibition mechanisms. Stem bark methanolic extracts demonstrate the highest total phenolic content at 193.58 ± 0.98 mg GAE/g, with potent tyrosinase inhibition at 157.07 ± 0.37 mg KAE/g and antimicrobial minimum inhibitory concentrations as low as 2.48 µg/mL against selected pathogens in vitro.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordBridelia ferruginea benefits
Bridelia ferruginea — botanical close-up
Health Benefits
**Antioxidant Protection**
Phenolics and flavonoids in stem bark and leaf extracts scavenge free radicals with DPPH values of 95.26–491.59 mg TE/g and ABTS values of 118.34–804.22 mg TE/g, supporting cellular defense against oxidative stress.
**Antimicrobial Activity**
Extracts inhibit Gram-positive bacteria, Gram-negative bacteria including Escherichia coli, yeasts, and dermatophytes with MIC values ranging from 2.48 to 62.99 µg/mL in vitro, consistent with traditional use as a mouthwash for oral infections.
**Cholinesterase Inhibition**
Methanolic extracts inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) at up to 6.36 mg GALAE/g, suggesting a theoretical basis for cognitive support and relevance to neurodegenerative disease research.
**Tyrosinase Inhibition**: Both stem bark (157
07 ± 0.37 mg KAE/g) and leaf (150.71 ± 0.57 mg KAE/g) methanolic extracts potently inhibit tyrosinase in vitro, indicating potential applications in hyperpigmentation and skin-related conditions.
**Glycemic Enzyme Inhibition**: Extracts inhibit α-amylase (up to 1
06 mmol ACAE/g) and α-glucosidase (notably in ethyl acetate fractions), suggesting a mechanistic basis for traditional use in metabolic conditions and potential antidiabetic relevance.
**Antiproliferative Activity**
In vitro studies show cytotoxic effects against HCT116 human colon carcinoma cells, though the specific molecular pathways, such as apoptosis induction or cell cycle arrest, have not yet been characterized.
**Traditional Sedative and Urogenital Use**
Ethnobotanical records document use for insomnia and gonorrhea in West African communities, with bark decoctions traditionally prepared for these purposes, though no mechanistic or clinical data are yet available to validate these specific applications.
Origin & History
Natural habitat
Bridelia ferruginea is a tropical African shrub or small tree native to West and Central Africa, growing widely across countries including Nigeria, Ghana, Cameroon, and Senegal in savanna woodlands, forest margins, and farmland edges. It thrives in humid to semi-arid tropical climates at low to moderate altitudes, tolerating a range of soil types. The plant is not formally cultivated on a large scale but is harvested from wild populations for local medicinal use, particularly by Yoruba-speaking communities in Nigeria where it is called 'iri,' and by Hausa-speaking communities where it is called 'kirni.'
“Bridelia ferruginea occupies a significant role in the traditional medicine of West African peoples, particularly among the Yoruba of southwestern Nigeria, who call it 'iri,' and the Hausa of northern Nigeria, who call it 'kirni.' Traditional healers have historically employed bark decoctions and leaf preparations for a range of conditions including insomnia, sexually transmitted infections such as gonorrhea, and oral hygiene as a mouthwash, reflecting a broad-spectrum empirical pharmacopoeia built over generations of use. The plant belongs to the family Phyllanthaceae and is part of a broader genus of Bridelia species used medicinally across sub-Saharan Africa, suggesting regional convergence in recognizing its therapeutic potential. While formal documentation in historical pharmacopeias is absent, its recurrent citation in ethnobotanical surveys of Nigerian and West African medicinal plants underscores its cultural relevance as a primary healthcare resource in communities with limited access to formal medicine.”Traditional Medicine
Scientific Research
All available research on Bridelia ferruginea consists exclusively of in vitro laboratory studies using crude methanolic, aqueous, and ethyl acetate extracts of leaves, stem bark, pericarp, and seeds; no animal model studies, pilot trials, or human clinical trials have been published as of the available literature. Antioxidant, enzyme inhibition, antimicrobial MIC determinations, and antiproliferative assays against HCT116 colon cancer cells constitute the entirety of the evidence base, providing mechanistic hypotheses but no translational or clinical validation. The evidence quality is pre-clinical and preliminary; studies lack dose-response relationships in living organisms, pharmacokinetic characterization, bioavailability assessments, or standardized extract preparations. While the in vitro data are internally consistent and suggest genuine bioactivity, the scientific evidence is insufficient to establish efficacy or safety for any human health condition, and independent replication in diverse laboratory settings is still limited.
Preparation & Dosage
Traditional preparation
**Traditional Bark Decoction**
Stem bark is boiled in water and the resulting decoction consumed orally or used as a mouthwash; no standardized volume or frequency has been established in the scientific literature.
**Leaf Infusion**
Leaves are steeped in hot water as a tea-like preparation in some West African traditions; specific volumes and durations are undocumented in peer-reviewed sources.
**Methanolic Extract (Laboratory Standard)**
Used in research at concentrations sufficient to generate quantifiable enzyme inhibition and antioxidant data; not available as a consumer supplement.
**Aqueous Extract (Laboratory Standard)**
88 mg GAE/g) and are the closest analog to traditional decoctions, but no dose translation to human use has been validated
Water-based extracts show high TPC (187.84 ± 1..
**No Standardized Supplement Form Exists**
No capsule, tablet, tincture, or standardized extract product with defined phytochemical content is commercially established or clinically validated for this ingredient.
**Dose Guidance**
No effective or safe supplemental dose has been determined; use of any preparation outside traditional ethnomedicinal contexts should be undertaken only under qualified medical supervision.
Nutritional Profile
Bridelia ferruginea is not consumed as a dietary food and lacks formal nutritional composition data for macronutrients or micronutrients. Phytochemically, the stem bark is the most phenolic-dense part of the plant, with methanolic extracts yielding 193.58 ± 0.98 mg GAE/g total phenolics and leaf methanolic extracts yielding 42.31 ± 0.39 mg RE/g total flavonoids. The pericarp and seeds also contain notable phenolics (9.84–125.59 mg GAE/g depending on extraction solvent) and flavonoids (7.17–44.67 mg QE/g), suggesting broader phytochemical distribution across plant parts. Bioavailability of these phenolics in human gastrointestinal conditions is entirely unstudied; solvent-dependent extraction differences (methanol > water > ethyl acetate for most phenolics) imply that water-based traditional preparations may not optimally extract all bioactive constituents present in the raw material.
How It Works
Mechanism of Action
The primary mechanism of Bridelia ferruginea extracts involves high-density phenolic and flavonoid constituents acting as hydrogen atom donors and electron donors that neutralize reactive oxygen species, as evidenced by potent DPPH, ABTS, and FRAP radical scavenging across all extract types. Inhibition of acetylcholinesterase and butyrylcholinesterase by methanolic extracts (up to 6.36 mg GALAE/g) is consistent with competitive or mixed-mode inhibition by polyphenols at the active site gorge of these enzymes, which theoretically prolongs acetylcholine availability at cholinergic synapses. Tyrosinase inhibition at 150–157 mg KAE/g likely reflects chelation of the copper active site within tyrosinase by phenolic hydroxyl groups, thereby reducing melanin biosynthesis and supporting antimicrobial membrane disruption through polyphenol intercalation into microbial lipid bilayers. Alpha-amylase and alpha-glucosidase inhibition by flavonoid-rich fractions suggests competitive blockade of carbohydrate-hydrolyzing enzyme active sites, which would theoretically attenuate postprandial glucose absorption, though these pathways remain unvalidated in intact biological systems.
Clinical Evidence
There are no clinical trials—randomized, observational, or otherwise—evaluating Bridelia ferruginea in human or animal subjects in the available scientific literature. All quantitative outcomes reported for this ingredient derive from cell-free biochemical assays (radical scavenging, enzyme inhibition kinetics) and microbiological MIC testing against isolated bacterial and fungal strains. Consequently, no effect sizes, confidence intervals, responder rates, or safety signals from controlled conditions in living systems are available to summarize. The gap between in vitro bioactivity data and clinical utility remains entirely unbridged, and any health claims beyond traditional use context are premature without further translational research.
Safety & Interactions
No formal safety studies, toxicological evaluations, or adverse event data exist for Bridelia ferruginea in humans or in validated animal models, making it impossible to define a safe dose range, maximum tolerable dose, or no-observed-adverse-effect level. The absence of documented side effects in the scientific literature reflects a gap in research rather than evidence of safety; reliance on centuries of traditional use as a proxy for safety is insufficient by modern pharmacovigilance standards. Potential drug interactions are entirely speculative but theoretically plausible given cholinesterase inhibition (possible additive effects with cholinesterase-inhibiting drugs such as donepezil or rivastigmine) and alpha-glucosidase inhibition (potential additive hypoglycemic effects with acarbose or antidiabetic medications). Use during pregnancy, lactation, or in pediatric populations is not supported by any safety data and should be avoided; individuals with liver or kidney conditions should exercise particular caution given the lack of metabolic and excretion profiling.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Bridelia ferruginea Benth.iri (Yoruba)kirni (Hausa)Ironwood BrideliaPhyllanthaceae shrub
Frequently Asked Questions
What is Bridelia ferruginea traditionally used for in West Africa?
In West African traditional medicine, Bridelia ferruginea is used primarily for insomnia, gonorrhea, and as a mouthwash for oral hygiene and infections. The Yoruba of Nigeria call it 'iri' and the Hausa call it 'kirni,' and both communities prepare decoctions from the stem bark and leaves for these purposes. No clinical trials have validated these traditional uses, but in vitro antimicrobial data showing MICs as low as 2.48 µg/mL are consistent with the mouthwash application.
Does Bridelia ferruginea have any scientifically proven health benefits?
Bridelia ferruginea has demonstrated antioxidant, antimicrobial, tyrosinase-inhibitory, cholinesterase-inhibitory, and antiproliferative activities exclusively in in vitro laboratory studies; no human or animal clinical trials have confirmed these effects in living biological systems. Stem bark methanolic extracts show particularly strong total phenolic content at 193.58 mg GAE/g and tyrosinase inhibition at 157.07 mg KAE/g. These findings are mechanistically interesting but cannot currently be translated into proven health claims for human use.
What is the recommended dosage of Bridelia ferruginea?
There is no established or scientifically validated dosage for Bridelia ferruginea in any supplement form; all research to date has used crude laboratory extracts rather than standardized consumer products. Traditional preparations involve boiling stem bark in water as a decoction, but no volume, concentration, or frequency has been formally defined. Without clinical trials and pharmacokinetic data, any specific dosage recommendation would be unsupported and potentially unsafe.
Is Bridelia ferruginea safe to use?
The safety of Bridelia ferruginea has not been evaluated in any formal toxicology study, human trial, or validated animal model, so it cannot be declared safe by contemporary scientific standards. The lack of documented adverse events in ethnomedicinal literature does not constitute a safety guarantee, and potential interactions with cholinesterase inhibitor drugs or antidiabetic medications are theoretically possible given its enzyme inhibition profile. Pregnant or breastfeeding individuals and those on prescription medications should avoid use until safety data are available.
Does Bridelia ferruginea have anticancer properties?
In vitro research has demonstrated antiproliferative activity of Bridelia ferruginea extracts against HCT116 human colon carcinoma cells, but the specific molecular mechanisms—such as apoptosis induction, cell cycle arrest, or signaling pathway modulation—have not been characterized. This finding is preliminary and based solely on cell culture assays; no animal tumor models, clinical trials, or mechanistic studies have been conducted. It would be inaccurate and premature to characterize Bridelia ferruginea as an anticancer agent based on current evidence.
What are the main active compounds in Bridelia ferruginea responsible for its health benefits?
Bridelia ferruginea contains significant concentrations of phenolics and flavonoids, particularly in its stem bark and leaf extracts, which are the primary bioactive compounds. These phenolic compounds demonstrate potent antioxidant activity with measured DPPH values of 95.26–491.59 mg TE/g and ABTS values of 118.34–804.22 mg TE/g, making them effective free radical scavengers. The presence of these secondary metabolites explains much of the plant's antimicrobial and antioxidant effects observed in traditional and scientific applications.
How does Bridelia ferruginea compare to other antimicrobial herbs in terms of effectiveness?
Bridelia ferruginea extracts demonstrate broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, including pathogenic strains like Escherichia coli, as well as yeasts and dermatophytes. This multi-pathogen inhibition profile is comparable to many traditionally used antimicrobial herbs, though direct comparative studies with other popular antimicrobial botanicals are limited. The herb's effectiveness appears related to its high flavonoid and phenolic content, which mechanistically disrupts microbial cell function.
Is Bridelia ferruginea more effective in fresh, dried, or extracted form?
Scientific studies on Bridelia ferruginea have primarily utilized stem bark and leaf extracts, which concentrate the active phenolic and flavonoid compounds, suggesting extract forms may deliver higher bioavailable concentrations of active constituents. However, traditional preparations in West Africa often employ dried plant material in decoctions or infusions, indicating traditional effectiveness across preparation methods. The optimal bioavailable form likely depends on the specific health application, with extracts potentially offering greater potency for antimicrobial or antioxidant purposes, while traditional decoctions maintain broader phytochemical profiles.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bridelia-ferruginea-bridelia-ferruginea-benth curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
